ORIOLE NCT02680587
ForHormone-sensitive oligorecurrent prostate ca, 1-3 mets on conventional imaging, ADT-free
19% vs 61%
7/36 vs 11/18, P=.005
TL;DR6-mo composite progression 19% vs 61% with SABR (P=.005); mPFS not reached vs 5.8 mo, HR 0.30.
Surfaced from a review's discussed trials
The actionable RT parameter is target selection, not dose: 16 of 36 SABR pts had PSMA-avid lesions left untreated because planning was blinded to PET, and those men progressed at 38% vs 5% by 6mo (distant MFS 6.0 vs 29.0mo, HR 0.19). That argues total consolidation of PET-avid disease, so PSMA-PET-based planning is the decision this moves.
In hormone-sensitive oligorecurrent prostate cancer with 1-3 conventionally imaged mets and no recent ADT, this supports deferring ADT with SABR to all PET-avid sites; it does not speak to de novo synchronous oligometastatic or castration-resistant disease.
Target selection, not dose, is the transferable parameter: planning was blinded to PSMA-PET, so 16/36 SABR pts had avid lesions untreated, and they progressed 38% vs 5% at 6mo with distant MFS 6.0 vs 29.0mo (HR 0.19). That argues for PET-based planning and total consolidation of avid disease. Dose and fractionation are not reported in source text.
The comparator here is observation with ADT deferral, not a systemic regimen, so the read is about sequencing: SABR pushed median PFS from 5.8 months to not reached in men deliberately kept off ADT. Whether that delay costs anything downstream is untested at 18.8 months median follow-up.
11 details 5 trials watching
Phase 2, 2-arm randomized trial across 3 US radiation facilities affiliated with one university hospital. 80 men screened, 54 randomized 2:1 to SABR or observation, accrual May 2016 to March 2018, data cutoff May 20 2019. Median follow-up 18.8 months (range 5.8-35.0).
Recurrent hormone-sensitive prostate cancer with 1 to 3 metastases detected on conventional imaging (CT, MRI, or bone scan), asymptomatic, arisen within the prior 6 months, no larger than 5.0 cm. Prior definitive treatment of the primary required; salvage prostate-bed or pelvic RT allowed. No ADT within 6 months of enrollment or 3 or more years total. Median age 68 in both arms; Gleason grade ran higher in the observation arm (mean 8 vs 7).
SABR to metastatic sites, with treatment planning blinded to PSMA-PET, so PET-avid lesions outside the conventional-imaging map were left untreated in 16 of 36 SABR pts. Dose and fractionation are not reported in the source text. Local control 98.9% at 6 months.
Primary: progression at 6 months, a composite of PSA rise, radiographic progression on conventional imaging, symptomatic progression, ADT initiation for any reason, or death. Secondary: SABR toxicity, 6-month local control, PFS, Brief Pain Inventory QoL, and concordance between conventional imaging and PSMA-PET.
No grade 3 or higher adverse events in either arm. No differences in Brief Pain Inventory scores between arms or within either arm over time.
Sits alongside STOMP, the other randomized trial of metastasis-directed therapy versus surveillance in oligorecurrent hormone-sensitive disease, and reaches the same directional conclusion from an independent population. What ORIOLE adds is the PSMA-PET consolidation question, which STOMP's choline-PET-selected design could not isolate.
The composite primary is driven partly by ADT initiation for any reason, a clinician decision made without blinding in an open trial, so the treating team's knowledge of arm allocation can move the endpoint directly. The PET-untreated-lesion comparison is a within-arm post-randomization subgroup (19 vs 16 men), not a randomized contrast, and the men whose conventional imaging missed more disease plausibly had more disease to begin with.
The trial makes two distinct claims and they carry different weight. That SABR beats observation on a 6-month composite in a 54-man phase 2 is a signal, not a standard; that leaving PSMA-avid disease untreated tracks with earlier and more distant failure is the finding that changed how the field plans these treatments, even though it rests on an observational contrast inside one arm.
CONSORT flow
Phase 2, N=54, 6-month composite primary including ADT initiation, median f/u 18.8mo. Hypothesis-generating for MDT; no OS or definitive endpoint.
- Does deferring ADT via SABR change overall survival n=162 · primary completion 2031-04 · randomises RDT alone vs RDT + ADT, PFS primary
- Optimal SABR dose and fractionation for prostate oligometastases recruiting OligoCare TwiCs (Trials Within Cohorts) Trial Comparing Acute Toxicity in Single-fraction vs Multiple-fraction SBRT for Metastasis-directed Treatment (SPRINT) Phase NAn=302 · primary completion 2029-02 · single- vs multi-fraction SBRT, acute toxicity primary
- Does PSMA-PET-guided total consolidation improve outcomes prospectively recruiting Treatment With Darolutamide +/- Radiation Therapy for Patients With a Castration Resistant Cancer and Metastases Detected by Functional Imaging Phase 3n=336 · primary completion 2029-10 · phase 3 darolutamide +/- SBRT to functional-imaging metsn=1000 · primary completion 2030-12 · prospective registry, PSMA PET-guided directed RTrecruiting Metastasis Directed Stereotactic Body Radiotherapy for Oligo Metastatic Hormone Sensitive Prostate Cancer Phase NAn=118 · primary completion 2031-12 · randomised MD-SBRT vs SOC, PSMA-PET-defined 1-3 mets
📚 Sources · 📄 1 paper
Abstract
The longer read
ORIOLE arrived at the same time as STOMP and pointed the same direction, and that convergence is most of why metastasis-directed therapy stopped being an unusual choice in oligorecurrent hormone-sensitive prostate cancer. Two small randomized trials, run in different health systems with different imaging pathways, both found that treating a handful of visible lesions delayed the events clinicians care about. Neither was powered for survival and neither claimed to be. The honest reading of the pair is that they established the state as worth treating prospectively, not that they settled dose, extent, or whether the delay in ADT translates into anything durable.
The headline number deserves less weight than it usually gets. Progression at 6 months was a composite that counted PSA rise, imaging progression, symptoms, death, and ADT initiation for any reason. In an open trial with no blinding, that last component is a decision made by a clinician who knows which arm the patient is in, and the observation arm is precisely where the reflex to start ADT is strongest. Some of the 61% versus 19% gap reflects biology and some reflects behavior, and the trial's design cannot separate them. The biochemical PFS result (HR 0.31) is less contaminated because PSA is measured rather than decided, and it moves in the same direction, which is reassuring without being conclusive at this sample size. A hazard ratio of 0.30 with an interval running to 0.81 in 54 men is compatible with a large effect and with a modest one.
The part of ORIOLE that changed practice was not the randomized comparison at all. Because treatment planning was blinded to PSMA-PET, 16 of 36 men in the SABR arm walked out with radiographically occult disease deliberately left in place, and the trial got an unplanned look at what incomplete consolidation costs. Those men progressed at 38% versus 5% by 6 months, and their median distant metastasis-free survival was 6.0 months against 29.0. The magnitude is striking enough that it reframed the operational question from whether to treat oligometastatic disease to which map to treat from. But this is a post-randomization comparison of two groups defined by what their scans showed, and the men with more PET-avid disease than conventional imaging revealed almost certainly had more disease burden overall. The comparison is confounded by the very thing it measures. It should raise confidence that PET-guided target selection matters; it does not establish that consolidating every avid lesion converts a poor-prognosis patient into a good one.
What should temper the transfer to a general clinic is how selected this population was. Enrollment required metastases visible on conventional imaging that appeared within the prior 6 months, capped at three and at 5.0 cm, in men off ADT and treated definitively for the primary. That is a narrow slice, and it excludes the de novo synchronous presentations and the castration-resistant patients for whom the same question is often asked. Gleason grade also ran higher in the observation arm, which in a 54-man trial is not a rounding error. Local control at 98.9% and no grade 3 or higher toxicity say the intervention is safe and does what it mechanically claims to do, which is the least surprising and most reliable result in the paper.
The question ORIOLE leaves open is whether delaying ADT by treating visible lesions changes anything a patient experiences years later, or whether it substitutes an early local intervention for a later systemic one at equivalent long-term cost. Answering that takes a trial powered for survival with follow-up measured in years, not a 6-month composite in 54 men.